Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Adv ; 10(10): eadj6380, 2024 Mar 08.
Article in English | MEDLINE | ID: mdl-38446889

ABSTRACT

Nanomaterials offer unique opportunities to engineer immunomodulatory activity. In this work, we report the Toll-like receptor agonist activity of a nanoscale adjuvant zeolitic imidazolate framework-8 (ZIF-8). The accumulation of ZIF-8 in endosomes and the pH-responsive release of its subunits enable selective engagement with endosomal Toll-like receptors, minimizing the risk of off-target activation. The intrinsic adjuvant properties of ZIF-8, along with the efficient delivery and biomimetic presentation of a severe acute respiratory syndrome coronavirus 2 spike protein receptor-binding domain trimer, primed rapid humoral and cell-mediated immunity in a dose-sparing manner. Our study offers insights for next-generation adjuvants that can potentially impact future vaccine development.


Subject(s)
COVID-19 , Zeolites , Humans , SARS-CoV-2 , Spike Glycoprotein, Coronavirus , Adjuvants, Immunologic , Endosomes , Toll-Like Receptors , Zeolites/pharmacology
2.
Vasc Endovascular Surg ; 50(2): 107-18, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26983667

ABSTRACT

Dyslipidemia, more specifically, high-serum low-density lipoproteins and low-serum high-density lipoproteins, are known risk factors for cardiovascular disease. The current clinical treatment of dyslipidemia represents the outcome of a large body of fundamental basic science research on lipids, lipid metabolism, and the effects of different lipids on cellular components of the artery, inflammatory cells, and platelets. In general, lower density lipids activate intracellular pathways to increase local and systemic inflammation, monocyte adhesion, endothelial cell dysfunction and apoptosis, and smooth muscle cell proliferation, resulting in foam cell formation and genesis of atherosclerotic plaque. In contrast, higher density lipids prevent or attenuate atherosclerosis. This article is part 1 of a 2-part review, with part 1 focusing on lipid metabolism and the downstream effects of lipids on the development of atherosclerosis, and part 2 on the clinical treatment of dyslipidemia and the role of these drugs for patients with arterial disease exclusive of the coronary arteries.


Subject(s)
Arteries/metabolism , Atherosclerosis/metabolism , Dyslipidemias/metabolism , Lipid Metabolism , Lipids/blood , Animals , Arteries/pathology , Arteries/physiopathology , Atherosclerosis/etiology , Atherosclerosis/pathology , Atherosclerosis/physiopathology , Biomarkers/blood , Dyslipidemias/complications , Dyslipidemias/pathology , Dyslipidemias/physiopathology , Humans , Inflammation Mediators/blood , Lipoproteins, HDL/blood , Lipoproteins, LDL/blood , Plaque, Atherosclerotic , Risk Factors , Signal Transduction
SELECTION OF CITATIONS
SEARCH DETAIL
...